Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
AssigneePrelude Therapeutics Incorporated
InventorsGanfeng Cao, Qun Li, Huaping Zhang, Hongwu Yu
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to pharmaceutically acceptable salts of the compound of Formula I (I). Pharmaceutical compositions comprising pharmaceutically acceptable salts of the compound of Formula I, as well as methods of their use and preparation, are also described.
Claims20
A pharmaceutical composition comprising a crystalline salt of compound with Formula I:
- and a pharmaceutically acceptable excipient, wherein the crystalline salt is a hydrochloride salt with Formula IA:
A method of treating a disease or disorder associated with aberrant PRMT5 activity in a subject comprising administering to the subject a crystalline HCl salt of Formula IA:
A method of treating a disease or disorder associated with aberrant PRMT5 activity in a subject comprising administering to the subject, a pharmaceutical composition comprising a crystalline salt of compound of Formula IA:
- and a pharmaceutically acceptable excipient in combination with one or more therapeutic agent.
Dependencies are inferred from the claim text.